Eric Pottier
Keine laufenden Positionen mehr
Profil
Eric Pottier worked as a Plant Manager at Eurand SpA.
He then worked as the Chief Pharmacist & Vice President-Supply Chain at Sangamo Therapeutics France SAS from 2014 to 2016.
Dr. Pottier holds a doctorate degree from L'Université d'Angers.
Ehemalige bekannte Positionen von Eric Pottier
| Unternehmen | Position | Ende |
|---|---|---|
| TXCELL | Geschäftsführer | 01.01.2014 |
Eurand SpA
 Eurand SpA Pharmaceuticals: MajorHealth Technology Eurand SpA is a specialty pharmaceutical company that develops, manufactures, and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. With integrated manufacturing and R&D facilities in the U.S. and Europe, the company has partnered with pharmaceutical companies licensing its four primary technology platforms: Customized Drug Release, Bioavailability Enhancement, Taste Masking or Oral Disintegrating Tablets, and Drug Conjugation. The company is headquartered in Pessano con Bornago, Italy. | Corporate Officer/Principal | - |
Ausbildung von Eric Pottier
| L'Université d'Angers | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Sangamo Therapeutics France SAS
 Sangamo Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics France SAS is a biotechnology company, which engages in developing platforms for T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases. The company was founded on April 12, 2001, and is headquartered in Valbonne-Sophia Antipolis, France. | Commercial Services |
Eurand SpA
Eurand SpA Pharmaceuticals: MajorHealth Technology Eurand SpA is a specialty pharmaceutical company that develops, manufactures, and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. With integrated manufacturing and R&D facilities in the U.S. and Europe, the company has partnered with pharmaceutical companies licensing its four primary technology platforms: Customized Drug Release, Bioavailability Enhancement, Taste Masking or Oral Disintegrating Tablets, and Drug Conjugation. The company is headquartered in Pessano con Bornago, Italy. | Health Technology |
